Zhitong Finance App News, Fangsheng Pharmaceutical (603998.SH) announced that on November 9, 2026, the company signed a “Drug Marketing License Transfer Agreement” with Hunan Oula Pharmaceutical Technology Co., Ltd. (“Ola Pharmaceutical”) and decided to transfer the marketing licenses it holds for “acetylcysteine granules” and “iprazole enteric tablets”.

Since the company decided on the development strategy of “becoming a health industry group with innovative traditional Chinese medicine as the core”, it has continued to increase investment in R&D and simultaneously reserve products with development potential through outsourcing to enrich the company's product pipeline, thereby speeding up the pace of development. Respiratory medicines represented by powerful loquat cream (honey) /dew and digestive and metabolic drugs represented by omeprazole enteric tablets and stomach healing capsules/granules have been set up in the company's multi-product matrix. After the completion of this transfer of “acetylcysteine granules” and “iprazole enteric tablets,” the main varieties in the above two product lines are expected to be effectively expanded. In the future, through the Group's brand empowerment, it is expected to provide the company with new profit growth points. The drug marketing license transferred this time is in line with the company's development strategy, which is conducive to promoting the integration and expansion of the industrial chain and enhancing the company's market competitiveness.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.